medigraphic.com

2020, Number 3

<< Back Next >>

Rev Clin Esc Med 2020; 10 (3)

Hidrops Fetal por aloinmunización RH tratado mediante transfusiones intrauterinas seriadas

Morales VVV, Picado ME, Córdoba ViS, Fonseca PG

Language: Spanish
References: 24
Page: 31-37
PDF size: 190.12 Kb.


ABSTRACT

Red blood cell alloimmunization is the second most common immune cause of perinatal hemolytic disease. Even though nowadays it is a less frequent condition due to the advances in its prevention through the administration of anti-Rh gamma globulin, it continues to present with compromising clinical manifestations for the fetus as fetal hydrops and anemia. This paper presents the case of a previously sensitized pregnant woman with Rh isoimmunization and manifestations of severe anemia and hydrops. The case is approached with serial intrauterine transfusions, both technical aspects and perinatal results are described.


REFERENCES

  1. Fuenzalida J, Carvajal J. Manejo de la embarazada con isoinmunización por anticuerpos irregulares. Rev Chil Obstet Ginecol. 2014;79(4):315-322.

  2. Ferrer R, Laurenzo B, Ávila E. Enfermedad hemolítica del recién nacido por isoinmunización a grupos sanguíneos menores. Un caso poco frecuente. Multimed Revista Médica Granma. 2016;20(3):624- 630.

  3. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstetrics & Gynecology. 2017;130(2):e57-e70.

  4. de Miguel J. Isoinmunización Eritrocitaria: Enfermedad Hemolítica Perinatal. Hidrops Fetal No Inmune. In: de Miguel Sesmero J, ed. by. Principios de Medicina Materno Fetal. 1st ed. Cantabria: Universidad de Cantabria; 2018. p. 431-441.

  5. Vizueta C, López B, Balon J, Zambrano R. Incompatibilidad Rh en el embarazo. Dom Cien. 2017;3(4):32-46.

  6. da Silva P, de María M, Borbonet D, Bravo A, Cedeño E. Manejo perinatal de la hidropesía fetal. Rev Latin Perinat. 2018;21(2):102-106.

  7. Takci S, Gharibzadeh M, Yurdakok M, Ozyuncu O, Korkmaz A, Akcoren Z et al. Etiology and Outcome of Hydrops Fetalis: Report of 62 Cases. Pediatrics & Neonatology. 2014;55(2):108-113.

  8. Borrell A. Guías Clínicas Medicina Materno-Fetal: Isoinmunización. Barcelona: Fundación Medicina Fetal Barcelona; 2014.

  9. Tipiani O, Rosales H, Arévalo H, Garay V, Aburto F, Hinojosa L. Anemia hemolítica fetal rápidamente progresiva en el pretérmino tardío: reporte de caso. Ginecol y Obstet Méx. 2018;86(11):749-754.

  10. Solís M. 94 de cada 100 nacimientos se atienden en maternidades de la CCSS [Internet]. Ccss.sa.cr. 2017 [citado 4 Junio 2020]. Disponible en: https://www. ccss.sa.cr/noticia?94-de-cada-100-nacimientos-seatienden- en-maternidades-de-la-ccss.

  11. McEwan A. Fetal anaemia. Obstetrics, Gynaecology & Reproductive Medicine. 2019;29(8):233-239.

  12. Cunningham G, Leveno K, Bloom S, Dashe J, Hoffman B, Casey B et al. Capítulo 15: Trastornos fetales. Williams Obstetricia. 25th ed. Ciudad de México: McGraw-Hill Education; 2019. p. 1-36.

  13. Abbasi N, Johnson J, Ryan G. Fetal anemia. Ultrasound in Obstetrics & Gynecology. 2017;50(2):145-153.

  14. Mari G, Norton M, Stone J, Berghella V, Sciscione A, Tate D et al. Society for Maternal- Fetal Medicine (SMFM) Clinical Guideline #8: The fetus at risk for anemia–diagnosis and management. American Journal of Obstetrics and Gynecology. 2015;212(6):697-710.

  15. Huertas E. Anemia fetal, diagnóstico y manejo actual. Rev Peru Ginecol Obstet. 2019;65(4):511-517.

  16. Martinez Portilla R, Lopez-Felix J, Hawkins Villareal A, Villafan Bernal J, Paz y Miño F, Figueras F et al. Performance of fetal middle cerebral artery peak systolic velocity for prediction of anemia in untransfused and transfused fetuses: systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology. 2019;54(6):722-731.

  17. Prefumo F, Fichera A, Fratelli N, Sartori E. Fetal anemia: Diagnosis and management. Best Practice & Research Clinical Obstetrics & Gynaecology. 2019; 58:2-14.

  18. Oepkes D, Seaward G, Vandenbussche F, Windrim R,Kingdom J, Beyene J, et al. Doppler Ultrasonography versus Amniocentesis to Predict Fetal Anemia. The New England Journal of Medicine. 2006; 355:156-164.

  19. 19. Borrell A. Guía Clínica: Isoinmunización. Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic de Barcelona. 2014. p. 1-10.

  20. Prevención, diagnóstico y manejo de la aloinmunización materno-fetal. México: Secretaría de Salud, 2011.

  21. Kenneth J, Moise Jr. Management of Rhesus Alloimmunization in Pregnancy. American College of Obstetricians and Gynecologists. 2008;112(1):164- 176.

  22. Zwiers C, van Kamp I, Oepkes D, Lopriore E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn – review on current management and outcome. Expert Review of Hematology. 2017;10(4):337-344.

  23. Friszer S, Maisonneuve E, Macé G, Castaigne V, Cortey A, Mailloux A et al. Determination of optimal timing of serial in-utero transfusions in redcell alloimmunization. Ultrasound in Obstetrics & Gynecology. 2015;46(5):600-605.

  24. Dodd J, Andersen C, Dickinson J, Louise J, Deussen A, Grivell R et al. Fetal middle cerebral artery Doppler to time intrauterine transfusion in red cell alloimmunization: a randomized trial. Ultrasound in Obstetrics & Gynecology. 2018;51(3):306-312.




2020     |     www.medigraphic.com